Long-acting insulin dosing via single fasting glucose measurement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin dosing methods for diabetes management are burdensome and often ineffective due to the need for frequent blood glucose measurements, leading to suboptimal glycemic control and increased treatment costs, while patients and healthcare providers perceive insulin therapy as complex and burdensome.
Innovation Solution
A simplified regimen where long-acting insulin dosing is titrated based on a single fasting blood or plasma glucose measurement, reducing the frequency of blood glucose testing without compromising therapeutic outcomes, allowing for patient-focused titration and empowerment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If frequent blood glucose measurements are performed to determine insulin dosing, then glycemic control precision is improved, but patient burden and treatment complexity increase
Solution Approach 1:
The patent extracts the essential information needed for insulin dosing by using a single fasting blood glucose measurement rather than multiple measurements. This takes out the unnecessary complexity of frequent testing while retaining the critical data point needed for effective glycemic control and insulin titration.
Solution Approach 2:
The patent applies partial action by using only one blood glucose measurement per dosing interval rather than multiple measurements. This single measurement is sufficient to guide insulin dosing decisions, reducing patient burden while maintaining adequate control precision through the use of structured titration algorithms.
2Manufacturing precision
If multiple blood glucose measurements are taken for insulin titration, then dosing accuracy is improved, but treatment time and cost increase
Solution Approach 1:
The patent extracts only the essential measurement needed for dosing accuracy - a single fasting blood glucose value - rather than requiring multiple measurements. This maintains dosing accuracy through standardized titration protocols while eliminating the time loss associated with repeated testing.
3Reliability
If frequent glucose monitoring is required, then therapeutic control is improved, but patient adherence decreases
Solution Approach 1:
The patent extracts the minimum necessary monitoring requirement - one fasting blood glucose measurement per dosing interval - to maintain therapeutic control. This reduction in monitoring frequency directly improves patient adherence while preserving reliable glycemic control through the use of evidence-based titration algorithms.
Solution Approach 2:
The patent enables patients to perform self-service insulin titration based on their own single daily fasting glucose measurement. This empowers patients to manage their own therapy without requiring frequent clinical visits or extensive monitoring, thereby improving adherence while maintaining therapeutic control.
Data Source
AI summary
The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c).